Abstract:

ABSTRACT Immunosuppressants play important roles on the short-term and long-term patient/graft survival in renal transplantation. Mizoribine (MZR) is similar to mycophenolate mofetil (MMF) in the mechanism of immunosuppression, and could be a substitute of MMF when the side-effects of MMF appear, like granulocytopenia, diarrhea or infection. The acute rejection rate may increase due to its less immunosuppressive in MZR group. However, high-dose MZR can reveal the advantage without increasing acute rejection rate, which can be selected as first-line treatment in the future.

Key words: renal transplantation,  immunosuppressant,  mizoribine,  infection